| Yang, Yang |
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 560 | RoW | Irinotecan Hydrochloride Injection, HX008, Placebo | Taizhou Hanzhong biomedical co. LTD | Stomach Cancer | 08/23 | 08/23 | | |
| Terminated | 3 | 372 | Europe, US, RoW | Pamrevlumab, FG-3019, Placebo | FibroGen | Idiopathic Pulmonary Fibrosis | 09/23 | 09/23 | | |
|
NCT05043688: Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. |
|
|
| Recruiting | 3 | 426 | RoW | Camrelizumab, radiotherapy | Zhigang Li, Jiangsu HengRui Medicine Co., Ltd. | Resectable Esophageal Squamous Cell Carcinoma | 12/28 | 12/30 | | |
NCT05250843: TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC |
|
|
| Recruiting | 2/3 | 90 | RoW | TACE/HAIC, Lenvatinib, Sintilimab, liver resection | Third Affiliated Hospital, Sun Yat-Sen University | Hepatocellular Carcinoma | 12/23 | 12/24 | | |
NCT06272214: Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy |
|
|
| Recruiting | 2 | 146 | RoW | Adjuvant radiotherapy, Observation | Zhejiang Cancer Hospital | Adjuvant Radiotherapy | 03/27 | 03/29 | | |
NCT06413342: Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 191 | RoW | Sintilimab | Zhejiang Cancer Hospital | Esophageal Cancer, Chemoradiotherapy, Sintilimab, Immunotherapy, Elderly Patients | 06/26 | 06/28 | | |
IIT-2024-238, NCT06509568: Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial） |
|
|
| Recruiting | 2 | 92 | RoW | Neoadjuvant chemoradiotherapy followed by immunotherapy, Neoadjuvant chemoimmunotherapy | Zhejiang Cancer Hospital | Esophageal Squamous Cell Carcinoma | 08/25 | 08/26 | | |
NCT05738057: Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 22 | RoW | Camrelizumab, Gemcitabine Injection, Cisplatin injection, Cisplatin-Eluting Beads, D-TACE | Hua Li | Unresectable Intrahepatic Cholangiocarcinoma | 03/25 | 03/26 | | |
NCT05417321: A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 80 | US, RoW | HB0036, Anti-PD-L1 and anti-TIGIT bifunctional molecule | Shanghai Huaota Biopharmaceutical Co., Ltd. | Advanced Solid Tumor, NSCLC | 08/25 | 08/25 | | |
NCT05940610: The Safety and Efficacy of MSC-EVs in Acute/Acute-on-Chronic Liver Failure |
|
|
| Withdrawn | 1/2 | 20 | RoW | MSC-EVs | Third Affiliated Hospital, Sun Yat-Sen University | Acute-On-Chronic Liver Failure, Acute Liver Failure | 09/24 | 10/25 | | |
NCT05881668: MSC-EV in Acute-on-Chronic Liver Failure After Liver Transplantation |
|
|
| Withdrawn | 1 | 30 | RoW | MSC-EV | Third Affiliated Hospital, Sun Yat-Sen University | Liver Failure, Acute on Chronic | 09/24 | 04/25 | | |
Neo-DRATEC, NCT03381651: Different Radiation Dose of Neoadjuvant Chemoradiation for Resectable Thoracic Esophageal Squamous Carcinoma |
|
|
| Completed | N/A | 147 | RoW | Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation, Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation | Zhejiang Cancer Hospital | Esophageal Carcinoma, Neoadjuvant Chemoradiotherapy, Surgery | 02/21 | 02/23 | | |
| Recruiting | N/A | 300 | US | T'ai Chi and Qigong Rehabilitation, Usual care | New York Presbyterian Hospital, Center for Taiji and Qigong Studies & Wa-Qi.com | Low Back Pain | 06/23 | 06/23 | | |
NCT04707053: Data Collection and Analysis in Brainstem Surgeries |
|
|
| Recruiting | N/A | 150 | Europe | | Cantonal Hospital of St. Gallen | Brainstem Lesion, Surgery, Intraoperative Neurophysiologic Monitoring | 12/23 | 12/25 | | |
| Recruiting | N/A | 1000 | RoW | internet plus model, control | Guizhou Provincial People's Hospital | Neonatal Jaundice | 10/24 | 05/25 | | |
UTTS, NCT06743477: A Clinical Study of Ultra-transplantation for the Treatment of Major Thalassemia Scheme |
|
|
| Not yet recruiting | N/A | 5 | RoW | Supergraft | Hu Peng | Stem Cell Transplantation | 12/26 | 12/26 | | |
NCT05707520: Long-term Benefit of MPA in Liver Transplantation |
|
|
| Recruiting | N/A | 500 | RoW | enteric-coated mycophenolate (MPAs), None MPA | Third Affiliated Hospital, Sun Yat-Sen University, Shulan (Hangzhou) Hospital, RenJi Hospital, The First Affiliated Hospital of Zhengzhou University, Beijing YouAn Hospital, Huashan Hospital, The Third Xiangya Hospital of Central South University, West China Hospital, Hebei Medical University Third Hospital, People's Hospital of Guangxi, Beijing Friendship Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Liver Transplant Rejection, Immunosuppressant Adverse Reaction | 06/23 | 09/23 | | |
| Guoying, Wang |
NCT04564313: Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation |
|
|
| Recruiting | 1 | 20 | RoW | Camrelizumab treatment | Third Affiliated Hospital, Sun Yat-Sen University | Hepatocellular Carcinoma, Liver Transplantation | 09/22 | 07/23 | | |
